DA

Dr. Aileen P. Ryan

Chief Development Officer

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Pipeline

DrugIndicationPhase
Sonelokimab (M1095)Hidradenitis Suppurativa (HS)Phase 3